Synthetic biology has changed, but the way DNA is made largely hasn’t. From mRNA therapeutics and gene editing to protein engineering and advanced vaccines, today’s most important applications demand DNA that is more accurate, more complex, and easier to use, without bacterial constraints. Yet much of the industry still depends on cloning workflows that introduce delays, contamination risk, and unnecessary limits on what can be built and how quickly teams can move. In this talk, we’ll explore why DNA remains one of the field’s most persistent bottlenecks, and why the future of DNA manufacturing will need to move beyond cloning. We’ll look at how cell-free approaches are removing bacterial constraints, and how the field is opening up through both cell-free DNA as a service and more accessible, kit-based assembly models that bring DNA manufacturing closer to the user. Together, these models have the potential to make advanced DNA easier to access, easier to integrate, and better aligned with the pace of modern biological development

For decades, DNA synthesis has been the limiting reagent in synthetic biology — reliable for short sequences, but increasingly error-prone and costly as designs scale. That ceiling is now cracking. New enzymatic synthesis platforms, error-correction chemistries, and assembly pipelines are extending what’s possible, opening the door to rapid construction of full pathways, microbial genomes, and even mammalian chromosomes. This session will explore how innovators are breaking past barriers, what technical and economic breakthroughs are needed next, and how longer, cheaper, and faster synthesis could fundamentally change how we design biology at scale.

The conversation would explore how leaders navigate the transition from breakthrough science to commercial reality. Rather than focusing on marketing tactics, the panel would examine the deeper challenge of narrative discipline as the industry moves from speculation to execution: how CEOs build credibility with investors, partners, and the public while still inspiring teams and markets to believe in long-term transformation.